Biologics have become a major part of pharmaceutical value, particularly in oncology, immunology, diabetes and other complex conditions. In the US, biologics represented only 5% of prescriptions but 51% of total drug spending in 2024, according to the FDA. At the same time, biosimilar competition is expanding: the FDA had approved 81 biosimilars covering 20 reference products by the end of 2025.
This creates an attractive but complicated market. A biologics portfolio can address significant clinical need and command high value, but commercialization depends on patient access, reimbursement, competitive differentiation, manufacturing capability and delivery infrastructure.
Patient Need Is Only the Starting Point
Biologics can address serious and chronic conditions, but the addressable market depends on more than disease prevalence.
The assessment should consider:
- Eligible patient population
- Diagnosis and treatment rates
- Current therapy penetration
- Treatment duration and lines of therapy
- Specialist availability
- Geographic concentration of patients
High biologic costs have historically limited access, particularly in low- and middle-income countries. It also identifies biosimilars as an important mechanism for expanding access to biological medicines.
A large untreated population can therefore indicate significant potential, but only where the healthcare system has the ability and willingness to diagnose, prescribe and finance treatment.
Nexdigm Evaluates Whether the Clinical Opportunity Can Become Commercial Demand
Nexdigm’s market assessment connects patient need with the factors that determine actual uptake.
The analysis can distinguish between potential patients and commercially addressable patients by examining treatment penetration, payer coverage, physician access and affordability. This is particularly important for high-cost biologics, where reimbursement restrictions can materially reduce the reachable patient population.
The result is a more realistic view of demand: not simply how many patients have a condition, but how many can realistically receive the product under the prevailing healthcare and reimbursement environment.
Competition Is Changing the Biologics Economics
Biologics face competition from both innovative therapies and biosimilars.
The FDA recorded a record 18 biosimilar approvals in 2024, while 2025 added further approvals across products including denosumab, ustekinumab, insulin aspart and others.
Competition can create significant pricing pressure. Nexdigm’s analysis found that biosimilars generated more than $13 billion in savings in the US through 2023, with more than half of that savings occurring in 2023 alone.
For a portfolio owner, this means competitive assessment should examine:
- Reference-product positioning
- Biosimilar presence and pipeline
- Patent and exclusivity timelines
- Clinical differentiation
- Physician switching behaviour
- Payer preferences
- Expected price erosion
A strong portfolio is therefore not necessarily the one entering the fastest-growing biologic category. It is the one with a defensible clinical and commercial position as competition evolves.
Pricing Has to Work for Both Payers and Patients
High prices can increase revenue per patient while limiting access. WHO supports tools such as reference pricing, tendering and lower co-payments to improve biologics affordability.
Pricing assessment should therefore examine:
- Reference-product pricing
- Reimbursement levels
- Payer restrictions
- Patient co-payments
- Tendering mechanisms
- Discounting and contracting
- Competitive alternatives
The commercial objective is not simply to maximize price. It is to determine where price, reimbursement and treatment volume can support sustainable portfolio economics.
Infrastructure Can Decide Whether the Portfolio Is Scalable
Biologics require specialized manufacturing, stringent quality controls and often temperature-controlled distribution. Administration may also depend on hospitals, infusion centres and trained specialists.
This makes infrastructure a key commercial consideration. Strong demand may not translate into viable market entry where cold-chain networks, specialist facilities or local manufacturing capacity are limited.
The Portfolio Needs to Be Tested at Market Level
A biologics portfolio can perform very differently across countries.
Nexdigm’s analysis of injectable-drug markets, for example, evaluates biologic portfolios alongside local manufacturing and fill-finish capacity, institutional tenders, specialty-pharmacy and home-infusion channels, cold-chain infrastructure, pricing and contracting.
This illustrates why country prioritization cannot rely on pharmaceutical spending alone. The relevant question is whether the market has the clinical, commercial and operational ecosystem required to support the portfolio.
How Nexdigm Assesses Biologics Market Feasibility
Nexdigm evaluates a biologics portfolio through five connected dimensions:
- Patient & Treatment Potential
Size eligible patients, treatment penetration, therapy duration and specialist access. - Competitive Positioning
Assess originators, biosimilars, pipelines, exclusivity and clinical differentiation. - Pricing & Reimbursement
Evaluate price corridors, payer coverage, reimbursement, contracting and affordability. - Infrastructure & Route to Patient
Assess manufacturing, cold chain, distribution, treatment centres, specialist capacity and administration requirements. - Portfolio & Market Prioritization
Compare markets and products based on demand, access, competitive pressure and commercial feasibility.
The assessment helps determine which markets to enter, which products to prioritize and what commercial or infrastructure requirements must be addressed before investment.
Nexdigm’s Biologics Market Assessment
Nexdigm supported a pharmaceutical company evaluating market opportunities across 3 target markets, assessing demand, competitive dynamics, pricing, market access and channel readiness. The engagement helped the client compare entry models, prioritize opportunities and assess partner readiness before committing resources to pharmaceutical commercialization.
A biologics portfolio succeeds when clinical need, access, differentiation, pricing and infrastructure align. Nexdigm’s biologics market feasibility study helps pharmaceutical companies assess these factors before investing in expansion or commercialization.
To take the next step, simply visit our Request a Consultation page and share your requirements with us.
Harsh Mittal
+91-8422857704
[email protected]